DERMATOMYOSITIS MARKET ANALYSIS

Dermatomyositis Market, by Type (Adult Dermatomyositis, Dermatomyositis Sine Myositis, and Juvenile (Childhood) Dermatomyositis (JDMS)), by Treatment Type (Anti-inflammatory Medication, Immunosuppressive Drugs, Immunoglobulin, and Others (Plasma Exchange, Monoclonal antibody among others)), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Europe, Asia Pacific, Middle East, Africa, and Latin America) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Sep 2022
Code : CMI5250
Pages :225
Formats :
Excel and PDF
Industry : Pharmaceutical

Market Challenges And Opportunities

Global Dermatomyositis Market: Restraint

The drugs used for the treatment of dermatomyositis may cause some side effects or adverse events, which is expected to hinder the global dermatomyositis market growth over the forecast period

For instance, the drug Octagam 10% (Immune globulin (human)) approved for adult dermatomyositis causes headache, nausea, anaphylactic reactions, thrombosis, and in rare cases may cause side effects such as hemolytic anemia, aseptic meningitis syndrome, and transfusion-related acute lung injury (TRALI)

Some of the common side effects of Dermatomyositis drugs are: Pain and swelling at injection site, mild headache, fainting and dizziness, back pain, abdominal pain and muscle cramps, and minor chest pain.